CBD shown to kill Gram-negative bacteria in pre-clinical studies
Researchers have shown that CBD can kill Gram-negative bacteria, which could lead to the first new class of antibiotics for resistant bacteria in 60 years.
List view / Grid view
Researchers have shown that CBD can kill Gram-negative bacteria, which could lead to the first new class of antibiotics for resistant bacteria in 60 years.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Scientists have identified a new family of biosynthetic genes in lichens with unknown functions, which could produce new molecules for the pharmaceutical industry.
Researchers at Ingenza and the University of Plymouth are using a machine learning and high‑throughput screening approach to discover novel antimicrobial therapies. In this article, Nikki Withers spoke to one of the researchers, Jack Kay, to hear about the current threat posed by antimicrobial resistance and how he hopes their…
In this in-depth focus find out how genetic screening can be used to customise healthcare and why scientists have turned to machine learning in the fight against antimicrobial resistance.
In this journal, find articles discussing antimicrobial resistance, exploring why inhibiting the interaction between SARS-CoV-2 and neuropilin-1 could help combat COVID-19, as well as how CRISPR can be used to enhance productivity in cell line development. Also in this issue, features on engineering new biologic drugs and precision medicine.
An inexpensive molecule showed efficacy against antibiotic-resistant Neisseria gonorrhoeae and Neisseria meningitidis in an animal model.
Altering the mastoparan-L (mast-L) peptide found in Vespula lewisii wasp venom, researchers created several novel antimicrobial molecules.
Exploring how the Ebola virus develops remdesivir resistance has highlighted a mutation that could allow SARS-CoV-2 to do the same.
A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
Tested on two assays, researchers have shown that Redx03863 and Redx04739 can combat tuberculosis and do not lead to resistance.
A compound extracted from the leaf of the American beautyberry re-sensitised methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics.
Researchers have created a method to promote the production of new antibiotic or antiparasitic compounds from the genomes of actinobacteria.
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.